Clinical Trial Update: ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis [Phase 3]

View source ↗

Summary

Phase 3 ALLEVIATE trial in allergic conjunctivitis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• Reproxalap (reproxalap)

Snippet

Sponsor: Aldeyra Therapeutics, Inc. | Conditions: Allergic Conjunctivitis | Phase 3 | Status: COMPLETED | Results posted: 2025-02-11